Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1593MR)

This product GTTS-WQ1593MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Facioscapulohumeral muscular dystrophy (FSHMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1593MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10101MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ13025MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ7395MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ8168MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ14348MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ6964MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ5368MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ1967MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS-15E
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW